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Ann E. Woolfrey,2,3 Antonio Bedalov,2,3 Jean E. Sanders,2,3
John M. Pagel,2,3 Eileen J. Sickle,2 Robert Witherspoon,2,3
Mary E. Flowers,2,3 Frederick R. Appelbaum,2,3 H. Joachim Deeg2,3In this prospective study 60 patients of median age 46 (range: 5-60 years), with acute myelogenous leukemia
(AML; n5 44), acute lymphoblastic leukemia (ALL; n5 3), or myelodysplastic syndrome (MDS; n5 13) were
conditioned for allogeneic hematopoietic cell transplantationwith a treosulfan/fludarabine (Flu) combination.
Most patients were considered at high risk for relapse or nonrelapse mortality (NRM). Patients received
intravenous treosulfan, 12 g/m2/day (n 5 5) or 14 g/m2/day (n 5 55) on days 26 to24, and Flu (30 mg/m2/
day) on days 26 to 22, followed by infusion of marrow (n 5 7) or peripheral blood stem cells (n 5 53)
from HLA-identical siblings (n 5 30) or unrelated donors (n 5 30). All patients engrafted. NRM was 5% at
day 100, and 8% at 2 years. With a median follow-up of 22 months, the 2-year relapse-free survival (RFS)
for all patients was 58% and 88% for patients without high-risk cytogenetics. The 2-year cumulative
incidence of relapse was 33% (15% for patients with MDS, 34% for AML in first remission, 50% for AML or
ALL beyond first remission and 63% for AML in refractory relapse). Thus, a treosulfan/Flu regimen was
well tolerated and yielded encouraging survival and disease control with minimal NRM. Further trials are war-
ranted to compare treosulfan/Flu to other widely used regimens, and to study the impact of using this regimen
in more narrowly defined groups of patients.
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/$36.00
6/j.bbmt.2010.05.007preparative regimens consisting of high-dose systemic
chemotherapy with or without total body irradiation
(TBI) are effective in eradicating leukemia and result
in relapse-free survival (RFS) rates of 10% to 80%,
depending on the patient’s disease status at the time of
HCT [1-4]. However, the probability of success with
this strategy is tempered by morbidity and mortality
because of regimen-related toxicity [5,6]. Reduced-
intensity conditioning (RIC) regimens have been used
with increasing frequency, particularly in older patients
with hematologic malignancies and in patients consid-
ered at high risk for treatment-related toxicity and
treatment-related mortality (TRM) associated with
high-dose conventional transplant regimens [7-10].
RIC regimens consistently result in less acute toxicity
and reduced nonrelapse mortality (NRM) compared
to conventional regimens, but in many studies, they
have been associated with higher cumulative incidence
rates of relapse [11-14]. An ideal transplant regimen
should generate sufficient disease control to allow for341
Table 1. Pretransplant Characteristics of 60 Patients Condi-
tioned with Treosulfan and Fludarabine
Characteristic No. of Patients
Age at transplantation (years)*
A <21 10
A 21-50 31
A 50-60 19
Sex (female:male) 36:24
Diagnosis and disease status at transplantation
A ALL, second/third remission† 3
A AML 44
First remission† 26
Second or greater remission† 10
Relapsed or primary refractory 8
A MDS‡ 13
RA 6
RAEB/RAEBT 7
Disease risk group (low:standard:high)§ 26:22:12
Cytogenetic risk group (good:intermediate:poor)¶ 16:8:36
HCT comorbidity index (0; 1-2; $3) 13:19:28
Pretransplant comorbidities and risk factors
A Previous malignancy 12
A Previous myeloablative HCT 10
A Underlying health conditions* 25
Donor type
A HLA-identical sibling 30
A HLA-matched unrelated donor 30
Stem cell source
A Bone marrow 7
A Filgrastim-mobilized PBPC 53
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous
342 Biol Blood Marrow Transplant 17:341-350, 2011E. R. Nemecek et al.sustained remissions without inducing substantial
toxicity and NRM.
Treosulfan (L-threitol-1,4-bis-methanesulfonate;
dihydroxybusulfan; IND 72479) is an alkylating agent
approved in European countries for the treatment of
ovarian carcinoma [15]. As a single agent, the most
common dose-limiting toxicities are mucositis, diar-
rhea, and myelosuppression [16]. Several European
teams have, therefore, evaluated treosulfan as part of
transplant conditioning regimens where bone marrow
suppression would not be a major concern [17-22].
Treosulfan has several characteristics that make it
attractive for use in HCT, including a highly
predictable pharmacokinetic (PK) profile, adequate
immunosuppressive activity to allow for engraftment
of donor cells across histocompatibility barriers, and
conceivably greater antileukemic activity than other
currently used agents [23-27]. Preliminary results of
European studies suggest low graft failure rates,
reduced NRM, and improved RFS. Here, we present
the results of the first trial conducted in the United
States, which combined treosulfan with fludarabine
(Flu) in a conditioning regimen for patients with
acute leukemia or myelodysplastic syndrome (MDS)
undergoing allogeneic HCT.leukemia; HCT, hematopoietic cell transplantation; HLA, human leuko-
cyte antigen; IPSS, International Prognosis Scoring System; MDS, myelo-
dysplastic syndrome; PBPC, peripheral blood stem cells; RA, refractory
anemia; RAEB/T, refractory anemiawith excess blasts/in transformation.
*Patients were 5-60 years (median 46 years) old.
†Minimal residual diseasewas present in 28% of the 39 patients with ALL
or AML in morphologic remission.
‡By IPSS criteria, 4 patients had intermediate-1, 5 intermediate-2, and 4
high-risk disease.
§Low-risk disease: AML or ALL in first remission, MDS with IPSS 5 0;
standard risk: ALL or AML in second or greater remission, MDS with
IPSS 0.5-2; high risk: relapsed/refractory ALL or AML, MDS with IPSS
$2.5.
¶Good risk cytogenetics: t(8;21), t(15;17), or inversion 16 for AML,
hyperdiploidy for ALL, -Y, del(5q), del(20q), or normal for MDS; poor
risk: 11q23 abnormalities, monosomy 7, monosomy 5, deletion 5q, or
abnormalities of 3q for AML, t(9;22) or extreme hypodiploidy for
ALL, chromosome 7 abnormalities in MDS,$3 chromosome abnormal-
ities for any disease type; Intermediate risk: all others.PATIENTS, MATERIALS, AND METHODS
Patient Characteristics
Sixty patients, median age 46 years (range: 5-60
years) were enrolled in this prospective, opened-label,
nonrandomized clinical trial conducted from Septem-
ber 2005 to December 2008 at the Fred Hutchinson
Cancer Research Center (FHCRC) in Seattle, WA,
and the Knight Cancer Institute at Oregon Health &
Science University (OHSU) in Portland, OR. Patient
characteristics are summarized in Table 1. Diagnoses
included acute lymphoblastic leukemia (ALL), acute
myelogenous leukemia (AML), and MDS.
The diagnosis was confirmed by internal review of
BM samples obtained before referral and by repeat BM
examination before initiation of the transplant condi-
tioning regimen. BM evaluations included morphol-
ogy, flow cytometry, and cytogenetic analysis. MDS
was classified according to WHO criteria and the Inter-
national Prognostic Scoring System (IPSS) [28,29].
Disease subtypes for ALL and AML were classified
using the French-American-British (FAB) system
[30,31]. Patients with leukemia were considered in
morphologic complete remission (CR) if they had
\5% blasts in a normocellular BM. Minimal residual
disease (MRD) was defined as the presence of
detectable disease by flow cytometry, cytogenetic
analysis, or fluorescein in situ hybridization (FISH) in
patients with\5% marrow blasts by morphology.Marrow cytogenetic studies at diagnosis and at
pretransplant relapse were available for all patients.
Cytogenetic risk was assigned following the combined
guidelines from cooperative groups [29,32-36].
Cytogenetic abnormalities were classified as good risk
if t(8;21), t(15;17), or inversion 16 was present in
patients with AML, hyperdiploidy in patients with
ALL and -Y, del(5q), del(20q), or normal karyotype in
patients with MDS. Poor-risk cytogenetics were
11q23 abnormalities or monosomy 7, monosomy 5,
deletion 5q or abnormalities of 3q for AML, t(9;22) or
extreme hypodiploidy for ALL, chromosome 7
abnormalities in MDS patients, and complex abnormal-
ities in$3 chromosomes for any disease type. All other
abnormalities were classified as intermediate risk.
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tion. Low risk included patients with AML or ALL in
first CR (CR1) or MDS with IPSS score 0, standard
risk patients with ALL or AML in second or greater
CR or MDS with IPSS risk score 0.5-2; high-risk pa-
tients had relapsed or refractory leukemia or MDS
with IPSS scores .2. Seventy-five percent of patients
were considered at high risk for treatment with conven-
tional transplant regimens, because of the secondary
nature of AML or MDS, previous HCT, or comorbid
conditions; 28 patients had transplant-specific comor-
bidity index (HCT-CI) scores of 3 or greater [37].
Patients with low general performance scores (ie,
Karnofsky or Lansky Play-Performance Scale score
\50% on pretransplant evaluation), HIV seropositivity,
uncontrolled systemic infections, active central nervous
system leukemia, or extramedullary disease or evidence
of major organ dysfunction were excluded. Major organ
dysfunction was defined as any of the following: cardiac
ejection fraction\35% or cardiac insufficiency requir-
ing treatment or symptomatic coronary artery disease;
impaired pulmonary function as evidenced by need for
continuous supplemental oxygen or diffusing capacity
of the lung for carbon monoxide (DLCO)\60% of
predicted; impaired renal function as evidenced by cre-
atinine clearance\50% corrected for body surface area
or serum creatinine.2 times the upper limit of normal
for age or dialysis-dependence; hepatic dysfunction
defined as total bilirubin or liver transaminase (AST/
ALT) values.2 times the upper limit of normal.
Patients, and legal guardians for patients younger
than 18 years, were informed of the investigational
nature of the study and signed consent forms approved
by the institutional review boards of the FHCRC
or OHSU in accordance with the Declaration of
Helsinki.
Donor Selection
Related donors were matched by intermediate
resolution molecular typing for HLA-A, -B, -C, and
-DQB1 and by high-resolution typing for DRB1.
Unrelated donors were allele matched for HLA-A,
-B, -C, and -DRB1 by high-resolution typing and
DQB1 by intermediate resolution typing. A single al-
lele disparity with the patient for HLA-A, -B, or -C
was allowed. The preferred hematopoietic stem cell
source was filgrastim-mobilized peripheral blood pro-
genitor cells. However, 7 patients received unmanipu-
lated BM cells either because of small donor size or
donor refusal to be treated with filgrastim.
Preparative Regimen
The preparative regimen was administered in
the outpatient setting for most adult patients.
Patients younger than 18 years received the preparative
regimen electively as inpatients. Treosulfan was givenintravenously on days 26 to 24 at doses of 12 g/m2/
day (total dose 36 g/m2/day) for the first 5 patients and
was then escalated to 14 g/m2/day (total dose 42 g/m2/
day) for the subsequent 55 patients after no toxicities
were observed with the lower dose. The latter dose
was set as the maximum tolerated dose based on results
of previous studies in Europe where dose-limiting toxic-
ities were observed with treosulfan doses above 42 g/m2/
day [16]. Flu was given intravenously at doses of 30 mg/
m2/day on days 26 to 22 (for a total of 150 mg/m2).
Ideal body weight was used for dosage calculations in pa-
tients for whom actual body weight exceeded 125% of
ideal body weight. Graft-versus-host disease (GVHD)
prophylaxis in most patients consisted of tacrolimus
(n 5 55) or cyclosporine (CsA; n 5 3) starting on day
21, combined with methotrexate (MTX) 15 mg/m2 ad-
ministered intravenously on day 11, and 10 mg/ m2/
dose on days 13, 16, and 111 after transplantation.
Two patients deemed at high risk for toxicity from
MTX received CsA starting on day23 in combination
with mycophenolate mofetil (MMF) starting on day 0.
Tacrolimus or CsA was maintained at therapeutic
plasma levels (per institutional standard practice proce-
dures) until at least day 150 and tapered through day
1180 if there were no signs of GVHD. If active
GVHD was present, treatment with tacrolimus or cy-
closporine was generally continued. MMF was
discontinued after day128 if the patient was engrafted
and free of GVHD.
PK Studies
Blood and urine samples were collected from the
first 16 patients in the study (12 adults and 4 children)
for treosulfan PK analysis. Samples were batched and
analyzed at the University of Essen, Germany (R.H.),
using methods previously described [16]. Blood sam-
ples were collected at 0, 2, 4, 5, 6, and 24 hours after
each treosulfan dose and plasma was separated by cen-
trifugation at 4C preceded by microfiltration. Urine
aliquots were collected at 4-hour intervals starting at
the end of administration of the first treosulfan dose
and for the entire period of treosulfan treatment
(72 hours), with sample pH adjusted to 5.5 with the
addition of citrate to prevent ex vivo degradation of
treosulfan. Urine samples were centrifuged at 4C
and directly analyzed. Analysis involved a validated
reverse-phase high-performance liquid chromatogra-
phy method and quantification by refractometrical
detection. Individual PK parameters were evaluated
by 2-compartment disposition modeling using TOP-
FIT software, version 2.0 (G. Fischer Verlag/VCH
Publishers, Stuttgart, Germany).
Engraftment and GVHD
Time to neutrophil engraftment was defined as the
first of 3 consecutive days with an absolute neutrophil
Table 2. Pharmacokinetic Parameters of Treosulfan*
Parameter Treosulfan 12 g/m2 Treosulfan 14 g/m2*
N 4 12
Age in years (median, range) 34 (18-47) 34 (5-55)
AUC (mg/L*h) 1365 ± 293 1309 ± 262
Cmax (mg/L) 461 ± 102 409 ± 84
Half-life (hours) 1.73 ± 0.10 1.83 ± 0.30
Vss (L) 16.9 ± 4.3 22.1 ± 3.8
Cltot (mL/min) 154 ± 35 185 ± 37
Urine excretion (%) 31 ± 2 27 ± 4
N indicates number of patients; AUC, area under the curve; Cmax, max-
imum plasma concentration; Vss, volume of distribution; Cltot, total sys-
temic clearance.
Results presented asmean6 standard deviation unless otherwise noted.
*Four children ages 5-17 years treated at the 14 g/m2 dose underwent
pharmacokinetic testing.
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engraftment was defined as the first of 3 consecutive
days with a platelet count .20  109/L and without
platelet transfusions. Acute and chronic GVHD
(aGVHD, cGVHD) were diagnosed, graded, and
treated as previously described [37,38]. Patients were
categorized according to the recently developed NIH
Consensus Criteria for diagnosis and staging of
cGVHD [38].
Supportive Care
All patients had central venous access lines placed
before HCT. Infection prophylaxis was given accord-
ing to standard institutional practices including broad-
spectrum antibiotics during the neutropenic period,
fluconazole, or other azole compounds for fungal
prophylaxis, trimethoprim-sulfamethoxazole for pre-
vention of Pneumocystis pneumonia, and acyclovir for
viral prophylaxis. Surveillance for cytomegalovirus
(CMV) reactivation or acquisition was carried out
weekly by polymerase chain reaction (PCR) testing
of plasma samples until day 100, and preemptive
anti-CMV therapy was initiated in patients who
showed an increase in viral copy numbers. Patients re-
mained hospitalized from the day of transplant (adults)
or from the time of initiation of conditioning (children
\18 years) until achievement of engraftment and
resolution of acute transplant-related complications.
Study Design and Statistical Methods
This opened-label, nonrandomized study was con-
ducted in 2 stages. The primary objective of phase I was
to determine the best of 2 doses of treosulfan that could
be used in combination with Flu. The best dose of treo-
sulfan was defined as the dose associated with accept-
able rates of regimen-related toxicity (RRT;\25%)
and graft failure (\5%). Regimen-related toxicity was
defined as organ toxicity observed within the first 28
days posttransplant, of grade 3 or greater by National
Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTCAE version 3.0; http://
ctep.cancer.gov/reporting/ctc.html), and not attribut-
able to primary or preexisting disease, GVHD, or in-
fection. Graft failure was defined as failure to achieve
an ANC of 0.5  109/L or greater by day 35 posttrans-
plant or an ANC\0.5 109/L after initial engraftment
without subsequent recovery and in the absence of
other contributing causes such as disease relapse,
medication effects, or infection.
As the lower treosulfan dose was well tolerated in
the first 5 patients, the dose was escalated to 14 g/
m2/day for 3 doses, and was given to the remaining
55 patients in phase II of the study. In addition to
further evaluating safety of the conditioning regimen
(ie, RRT and graft failure) in a larger group of patients,
the objective of the second phase was to determine ifthe drug combination proved sufficiently attractive
for further study, as evidenced by an incidence of
NRM of\25% at 1 year.
Estimates of overall survival (OS) and RFS were
calculated using the method of Kaplan and Meier. Re-
lapse or death, whichever occurred first, was consid-
ered as failure for the endpoint of RFS. Cumulative
incidence curves were used to estimate the probabili-
ties of GVHD, relapse, and NRM. Death was treated
as a competing risk for GVHD and relapse. Relapse
was considered a competing risk for NRM. Simple
proportions were used to summarize patient pretrans-
plant characteristics and to estimate the probabilities
of RRT. The statistical significance of differences in
event rates was evaluated with the Cox regression
model. Explanatory variables examined for the regres-
sion models included patient age, disease status, donor
type, and HCT-CI [39]. All reported 2-sided P-values
from regression models were derived from the Wald
test. The statistical analysis was performed on SAS
software version 9 (SAS Institute, Inc., Cary, NC).
Results were analyzed as of June 30, 2009.RESULTS
Treosulfan Dose Escalation and PKs
Five patients received treosulfan at 12 g/m2/dose.
After no limiting toxicities were observed at that
dose, the remaining 55 patients received treosulfan at
14 g/m2/dose. Analysis of treosulfan PK was con-
ducted in 16 patients treated consecutively, including
4 of the 5 patients receiving 12 g/m2 (all adults) and
12 patients receiving 14 g/m2 (4 children, 12 adults).
Table 2 shows the PK parameters observed by dose
group.
Engraftment and Donor Cell Chimerism
One patient died on day 10 from pulmonary asper-
gillosis (present pretransplant) and was not evaluable
for engraftment. The remaining 59 patients achieved
Table 3. Nonhematologic Toxicities in 60 Patients
Grade (No. of Patients)*
Organ System 1 2 3 4
Cardiac 2 2 1 0
Bladder 5 1 0 0
Hepatic 23 13 0 0
Mucosal/gastrointestinal 18 13 6 1
Neurologic 0 0 0 0
Pulmonary 5 8 2 0
Renal 17 9 1 0
Skin/dermatitis 4 7 0 0
*Grading according to National Cancer Institute Common Terminology
Criteria for Adverse Events (NCI-CTCAE), and not attributable to
primary or preexisting disease, graft-versus-host disease (GVHD), or
infection.
Figure 1. NRM. Estimates (solid line) and 95% confidence intervals
(dotted lines) are shown.
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11-26) days. Platelet engraftment occurred at a median
of 16 (range: 9-92) days. Complete donor T cell
chimerism (ie, .95% CD31 cells of donor origin)
was achieved by day 28 in 82% (49/60) and by day
100 in 85% (40/47) of patients evaluated. Complete
donor myelogenous cell chimerism (ie, .95% CD33
cells of donor origin) was achieved by day 28 in 97%
(58/60) and by day 100 in 97% (46/47) of patients eval-
uated. The 7 patients with mixed chimerism at day 100
showed 100% donor cell chimerism at 1 year.
RRTand TRM
Observed toxicities are summarized in Table 3.
Mild-to-moderate mucositis (NCI grades 1-2) was
observed in 52% of patients during the neutropenic
phase. A temporary mild-to-moderate elevation of he-
patic transaminases was seen in 60% of patients, typi-
cally during the days when MTX was administered.
No sinusoidal obstruction syndrome of the liver oc-
curred. Dermatitis of grades 1-2, consisting of a self-
limited skin rash, was observed in 18% of patients.
Grade 4 RRT was noted in 1 patient (1.5%), and con-
sisted of severe mucositis requiring temporary
intubation (n 5 1). Day 100 NRM was 5.0% (95%
confidence interval [CI] 0-10.5] (Figure 1). The esti-
mated NRM at 2 years was 8.3% (95% CI 1.3-15.3).
Causes of death included cGVHD (n 5 2), fungal
infection (n 5 2), and intracranial hemorrhage
(n5 1). All 5 patients who died from nonrelapse causes
had high comorbidity scores (4-5) prior to transplant,
and 3 were recipients of second allogeneic HCT.
NRM was observed in 1 of 10 patients younger than
21 years and 4 of 19 patients older than 50 years.
GVHD
Thirty-six of 58 evaluable patients experienced
aGVHD, which was grade I in 4, grade II in 27, and
grade III in 5 patients, for a cumulative incidence of
grades II-III of 55.2% (95% CI 42.4-68.0) at 90 days
after HCT. No grade IV GVHD was observed.cGVHD developed in 31 of 48 evaluable patients
(65%). Resolution of cGVHD, evidenced by discon-
tinuation of immunosuppressive therapy, was achieved
in 21 of these 31 patients (68%) at a median of 18
(range: 8-26) months after HCT.Survival and Disease Recurrence
Thirty-five patients were alive and disease-free at
a median follow-up of 22 (range: 14-41) months.
The estimated OS at 2 years was 65% (95% CI 51.5-
75.6), and RFS 58% (95% CI 44.9-69.6) as illustrated
in Figure 2. Source of stem cells, comorbidity score,
disease risk, and cytogenetic risk categories were the
strongest predictors of RFS in a multivariable model
(Table 4a). Figure 3 shows the unadjusted RFS survival
in subsets defined by disease risk (Figure 3A) and cyto-
genetic risk categories (Figure 3B). Estimates of RFS
at 2 years were 68%, 54%, and 44% for patients with
low, standard, and high risk by disease category,
respectively (P\ .001 for linear trend in an adjusted
model). Patients with high-risk cytogenetics had lower
RFS than patients with standard or intermediate cyto-
genetic risk (39% versus 88% at 2 years, P\ .001 in an
adjusted model). Transplantation from unrelated
donors and the presence of MRD at the time of
HCTwere associated with inferior RFS in univariable
models; however, after adjustment for cell source,
disease risk, and cytogenetic risk, these factors were
no longer significant predictors of RFS. Four of 9
patients receiving second transplantation are alive
and leukemia-free with median follow-up of 19 (range:
15-31) months. Transplant number was a significant
predictor of event-free survival (EFS) in an unadjusted
model (HR 5 3.2, 95% CI 1.3-7.6, P 5 .01), but
no longer statistically significant after adjustment
for cell source, disease risk, and cytogenetic risk
(P 5 .15). Age was not a significant predictor of OS
or RFS on multivariate analysis.
Figure 2. OS and RFS. Estimates of OS (left) and RFS (right) and 95% confidence intervals (dotted lines) for all patients.
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all patients was 33% (95% CI 21.4-45.3). Patient age,
cell source, disease risk, and cytogenetic risk categories
were the strongest predictors of relapse in a multivari-
able model (Table 4b). The 2-year estimates of relapse
were 35% (95% CI 16.3-52.9) for patients with AML
in CR1, 50% (95% CI 15.4-84.6) for AML or ALL be-
yond CR1, 63% (95% CI 29.0-96.0) for AML not in
remission, and 15% (95% CI 0-35.0) for patients
with MDS (Figure 4).Table 4. MultivariableAnalyses for Relapse-Free Survival and
Relapse
a) Relapse-free survival by clinical characteristics
HR (95% CI) P-Value
Comorbidity score* 1.3 (1.0-1.7) .02
Cell source
 PBPC 1.0
 Bone marrow 7.2 (2.0-26.2) .003
Disease risk
 Low 1.0
 Intermediate 3.8 (1.3-11.1) .01
 High 7.9 (2.7-23.3) <.001
Cytogenetic risk
 Standard or intermediate 1.0
 High 15.5 (4.3-56.7) <.001
b) Relapse by clinical characteristics
HR (95% CI) P-Value
Age† 0.7 (0.5-1.0) .02
Cell source
 PBPC 1.0
 Bone marrow 9.6 (2.4-37.6) .001
Disease risk
 Low or intermediate 1.0
 High 7.0 (2.1-22.9) .001
Cytogenetic risk
 Standard or intermediate 1.0
 High 8.0 (2.2-29.1) .002
CI indicates confidence interval; HR, hazard ratio; PBPC, peripheral
blood progenitor cells.
*Continuous variable with truncation at score of 5 (ie, 1, 2, 3, 4, $5).
†HR corresponds to difference of 10 years in age.DISCUSSION
The present study shows that a combination of
treosulfan and Flu provides effective conditioning for
allogeneic HCT from related and unrelated donors in
patients with hematologic malignancies. Engraftment
was achieved in all evaluable patients. NRM was low,
5% at day 100, and 8% at 2 years, in a cohort that in-
cluded 22 patients who had either secondary
leukemia or MDS, or had previously received a trans-
plant using conventional high-dose conditioning regi-
mens. In addition, 47% of patients had transplant
comorbidity scores of 3 or higher.
Analysis of survival, based on widely accepted risk
factors, showed a clear separation of results between
patients with high risk compared to intermediate- or
good-risk cytogenetics and a similar separation of pa-
tients with respect to disease risk. Dependent upon dis-
ease category, the cumulative incidence rates of relapse
ranged from 15% to 63%, and RFS at 2 years from
39% to 88%. Taken together, these results suggest
that a combination of treosulfan and Flu would be an
excellent conditioning regimen for patients with low-
or standard-risk cytogenetics. In high-risk patients,
however, the observed relapse rate was high. As the
toxicity profile of the regimen was excellent, it may
be possible to add other components, for example,
low-dose TBI [40] to this combination to increase
antileukemic efficacy without unacceptably increasing
toxicity. Of interest in this context is a recent preclin-
ical study that provides evidence for radiation sensiti-
zation by treosulfan [41].
The current results are in good agreement with
reports by others in regard to both toxicity and efficacy.
Beelen and colleagues [42] reported results in 18
patients, 19 to 64 years of age with various hematologic
malignancies, who were conditioned with treosulfan
(36-42 g/m2 over 3 days) and cyclophosphamide (Cy;
120 mg/kg over 2 days) and transplanted from HLA-
identical siblings. The 1-year RFS was 56%, and 22%
of patients died from nonrelapse causes. The major
Figure 3. RFS by disease risk (A) and cytogenetic risk (B). (A) Disease risk was classified using CIBMTR criteria. Low risk: ALL or AML in first remission
or MDS-RA; standard risk: AML or ALL in second or greater remission; high risk: relapsed or primary refractory ALL or AML, RAEB and RAEBT. (B)
Cytogenetic abnormalities were classified as favorable if t(8;21), t(15;17) or inversion 16 for AML or hyperdiploidy for ALL were present; high risk in-
cluded 11q23 abnormalities, monosomy 7, monosomy 5, deletion 5q or abnormalities of 3q, t(9;22), extreme hypodiploid for ALL or complex abnor-
malities (.3 chromosomes); intermediate risk included all other abnormalities.
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Casper and colleagues [17] reported results in 56
patients, 18 to 66 years of age, with various hematologic
malignancies, who were conditioned with treosulfan
(30, 36, or 42 g/m2 over 3 days) and Flu (150 mg/m2
over 5 days), and transplanted from HLA-identical re-
lated or unrelated donors. The source of stem cells was
marrow or mobilized peripheral blood progenitor
cells, and unrelated transplant recipients were also
given antithymocyte globulin (ATG). The 1-year
RFS (median follow-up 21 months) was 53%. The ma-
jor toxicities were mucositis/enteritis and transaminase
elevations; NRM was 20%.
Although no controlled prospective data are avail-
able, these results with treosulfan in combination
with Flu are comparable to those obtained with tar-
geted busulfan (Bu) combined with Flu or Cy [43,44].
The incidence of GVHD in our study was also
comparable to that observed in earlier Bu trials [45], in-
dicating that the reduced overall toxicity was not asso-Figure 4. Cumulative incidence of relapse by diagnosis and disease sta-
tus at transplantation.ciated with a change in the incidence of GVHD. Some
investigators have incorporated serotherapy with ATG
or alemtuzumab into treosulfan-containing regimens,
thereby possibly lowering the frequency of GVHD
when using unrelated donor sources [17,18,46]. Such
a strategy has also been successful with Bu-containing
regimens [47].
Most encouraging in the current trial were the low
rates of severe toxicity and NRM of 8% at 2 years. Mild
mucositis and reversible transaminase elevations were
the most frequent complications. Although Bu, simi-
larly, has not been associated with severe mucositis,
hepatotoxicity has been a concern, particularly with
the oral preparation, and when followed by the admin-
istration of Cy [48]. Treosulfan is spontaneously ‘‘acti-
vated’’ into an epoxy compound that crosslinks DNA.
Because enzymatic activation is not required, hepatic
metabolic pathways are bypassed. The half-life of treo-
sulfan is similar to that of Bu (approximately 1.7-2
hours), although cumulative renal excretion is higher
(50% versus 20%) [23]. It is possible that these differ-
ences in hepatic metabolism contribute to the better
clinical tolerability observed with treosulfan to date.
Although NRM was low, relapse and associated
mortality were considerable problems. The 2-year
cumulative incidence of relapse was 33%. In patients
with relapsed or refractory AML, the incidence was
as high as 62%, compared to 15% in patients with
MDS of any risk category. Although the numbers in
these subcohorts of patients were too small to draw
firm conclusions, the data suggest that a treosulfan/
Flu regimen might be most effective and acceptable
in patients with relatively low-risk disease, because of
the remarkably low NRM, the very low incidence of
relapse, and a 2-year RFS of 88%. The encouraging
RFS of 44% in patients undergoing second transplan-
tation also suggests that this regimen may be of
348 Biol Blood Marrow Transplant 17:341-350, 2011E. R. Nemecek et al.promise for this group of patients at very high risk for
treatment failure.
The excellent tolerability of the treosulfan/Flu
combination may allow for ‘‘intensification’’ of this
regimen with the aim of achieving greater antileukemic
efficacy. An escalation of the treosulfan dose is not at-
tractive based on earlier data reported by European
groups, which suggest that 14 g/m2 is the maximum
dose that can be given without inducing significant gas-
trointestinal symptoms (ie, enteritis and diarrhea) [16].
In fact, PK studies included in the present trial, along
with previously published data, indicate that maximum
plasma concentrations as well as AUC values for treo-
sulfan at the lower dose of 12 g/m2 are comparable to
those achieved at 14 g/m2. A further dose increase
would be unlikely to provide greater efficacy. Given
the possible radiosensitizing effects of treosulfan [41],
appropriate sequencing of administration of radiation
and treosulfan might enhance the antileukemic effect,
although such a regimen would also likely increase
the risk of mucositis or gastrointestinal complications.
Incorporation of different modalities, such as antibody
conjugates or posttransplant interventions, may also be
attractive [49]. It may also be of interest to compare
treosulfan-containing regimens to other protocols cur-
rently in use, such as Flu/melphalan combinations [14].
An ongoing prospective randomized study at European
centers is comparing a treosulfan/Flu combination
with a Bu/Flu regimen in adult patients with myeloge-
nous malignancies.
Although the definition of what constitutes an RIC
regimen varies, there is general consensus that the goal
of such a regimen must be to achieve maximum disease
control with minimal toxicity [50,51]. A treosulfan/Flu
combination represents 1 such effort toward this goal.
Determining which patient and disease categories are
likely to derive the greatest benefit from this regimen
requires further investigation.ACKNOWLEDGMENTS
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